ADVA
ADVA (ISIN: DE0005103006), a leading provider of open networking solutions for the delivery of cloud and mobile services, reported financial results for Q4 2020 and full year 2020 ended on December 31, 2020. The results have been prepared in accordance with International Financial Reporting Standards (IFRS).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005994/en/
Q4 2020 financial summary1
(in thousands of EUR) |
Q4 |
Q4 |
Change |
Q3 |
Change |
|||||
|
2020 |
2019 |
|
2020 |
|
|||||
|
||||||||||
Revenues |
140,572 |
151,135 |
-7.0% |
146,676 |
-4.2% |
|||||
Pro forma gross profit |
54,641 |
54,633 |
0.0% |
51,930 |
5.2% |
|||||
in % of revenues |
38.9% |
36.1% |
2.8pp |
35.4% |
3.5pp |
|||||
Pro forma operating income |
14,343 |
10,333 |
38.8% |
11,053 |
29.8% |
|||||
in % of revenues |
10.2% |
6.8% |
3.4pp |
7.5% |
2.7pp |
|||||
Operating income (loss) |
13,085 |
5,438 |
140.6% |
9,768 |
34.0% |
|||||
Net income |
13,249 |
2,522 |
425.3% |
6,671 |
98.6% |
|||||
|
||||||||||
(in thousands of EUR) |
Dec. 31 |
Dec. 31 |
Change |
Sep. 30 |
Change |
|||||
2020 |
2019 |
2020 |
||||||||
Cash and cash equivalents |
64,881 |
54,263 |
19.6% |
68,293 |
-5.0% |
|||||
Net debt |
25,545 |
61,146 |
-58.2% |
35,009 |
-27.0% |
|||||
Net working capital |
129,853 |
128,150 |
1.3% |
124,043 |
4.7% |
|||||
1 Potential difference due to rounding |
||||||||||
Q4 2020 IFRS financial results
Revenues in Q4 2020 reached EUR 140.6 million, down by 4.2% from EUR 146.7 million in Q3 2020 and down by 7.0% compared to EUR 151.1 million in the same year-ago period. The decrease in revenues is primarily due to the devaluation of the US dollar compared to the euro. In addition, due to lockdown tightening again, some orders had to be postponed to the following quarter.
Pro forma gross profit in Q4 2020 increased by 5.2%, reaching EUR 54.6 million (38.9% of revenues) compared to EUR 51.9 million (35.4% of revenues) in Q3 2020. Compared to EUR 54.6 million reported in the year-ago quarter, pro forma gross profit remained stable in absolute terms. However, in relation to revenues, an increase of 2.8 percentage points from 36.1% to 38.9% was achieved. This increase can mainly be attributed to the stronger euro compared to the US dollar. Compared to the year-ago quarter, Q4 2020 benefited from lower US tariffs due to the relocation of production facilities out of China. In addition, the above-average profitable technology area of network synchronization recorded a very successful final quarter.
Pro forma operating income for Q4 2020 was EUR 14.3 million (10.2% of revenues) and increased considerably by 29.8% compared to EUR 11.1 million (7.5% of revenues) in Q3 2020. Compared to the year-ago quarter, pro forma operating income improved substantially by 38.8% from EUR 10.3 million (6.8% of revenues). In addition to the higher gross profit, this substantial margin improvement is mainly due to the cost improvement measures introduced in 2019 and reduced discretionary spending.
Consequently, operating income for Q4 2020 of EUR 13.1 million increased by 34.0% from EUR 9.8 million reported for Q3 2020 and significantly increased by 140.6% from EUR 5.4 million in the same year-ago quarter. While Q4 2019 was negatively impacted by one-off expenses of EUR 3.2 million resulting from the introduced cost improvement measures, Q4 2020 was positively impacted by the renewed cost basis.
Net income reached EUR 13.2 million in Q4 2020, substantially up by 98.6% from EUR 6.7 million in Q3 2020 and significantly up by 425.3% from EUR 2.5 million in Q4 2019.
The company’s cash and cash equivalents totaled EUR 64.9 million, representing a slight decrease of EUR 3.4 million compared to EUR 68.3 million at the end of Q3 2020. Year-over-year cash and cash equivalents substantially increased by EUR 10.6 million from EUR 54.3 million at the end of Q4 2019. The higher cash balance is mainly the result of the improved profitability.
Consequently, net debt in Q4 2020 decreased by EUR 9.5 million to EUR 25.5 million from EUR 35.0 million at the end of Q3 2020 and improved significantly by EUR 35.6 million compared to Q4 2019 (EUR 61.1 million).
Net working capital at quarter-end was EUR 129.9 million and increased by EUR 5.9 million compared to EUR 124.0 million at the end of Q3 2020. This was particularly due to measures to maintain the supply chain and the associated reduction in trade payables.
Full year 2020 financial summary1
(in thousands of EUR) |
2020 |
2019 |
Change |
|||
Revenues |
564,958 |
556,821 |
1.5% |
|||
Pro forma gross profit |
199,050 |
195,364 |
1.9% |
|||
in % of revenues |
35.2% |
35.1% |
0.1pp |
|||
Pro forma operating income |
33,832 |
24,811 |
36.4% |
|||
in % of revenues |
6.0% |
4.5% |
1.5pp |
|||
Operating income (loss) |
27,473 |
12,003 |
128.9% |
|||
Net income |
20,314 |
7,045 |
188.3% |
|||
|
||||||
(in thousands of EUR) |
Dec. 31 2020 |
Dec. 31 2019 |
Change |
|||
Cash and cash equivalents |
64.881 |
54,263 |
19.6% |
|||
Net debt |
25,545 |
61,146 |
-58.2% |
|||
Net working capital |
129,853 |
128,510 |
1.3% |
|||
1 Potential differences due to rounding |
||||||
Full year 2020 IFRS financial results
For the full year 2020, revenues increased by 1.5% from EUR 556.8 million in 2019 to EUR 565.0 million. Revenues were at the lower end of the guidance corridor of between EUR 565 million and 580 million. Despite the current pandemic, demand in 2020 was robust. Home office, the increased use of e-learning, video conferencing and streaming services have increased network utilization significantly, while investments in network access solutions for enterprises have decreased. On the other hand, the US dollar, which continued to weaken against the euro, had a negative impact on US-denominated revenues, especially in the second half of the year.
Pro forma gross profit increased by 1.9% from EUR 195.4 million in 2019 to EUR 199.1 million in 2020. While in the first half of the year, gross profit was negatively impacted, particularly by the effects of the Covid-19 pandemic, the second half of the year benefited from revenues with higher margins and the ongoing US dollar devaluation.
Pro forma operating income for 2020 significantly increased by 36.4% from 24.8 million or 4.5% of revenues in 2019 to EUR 33.8 million or 6.0% of revenues. Pro forma operating income was at the top end of the guidance corridor of between EUR 5.0% and 6.0%. In addition to the higher gross profit, this substantial margin improvement is mainly due to the cost improvement measures introduced in 2019 and reduced discretionary spending.
Operating income for 2020 reached EUR 27.5 million compared to EUR 12.0 million in 2019 and increased significantly by 128.9%. While the previous year was negatively impacted by EUR 5.7 million one-off expenses in connection with the cost reduction measures, the improved cost base in 2020 contributed positively to profitability.
Consequently, net income increased significantly from EUR 7.0 million in 2019 by 188.3% to EUR 20.3 million in 2020.
Basic and diluted earnings per share in 2020 amounted to EUR 0.40, both compared to basic and diluted earnings per share of EUR 0.14 in 2019.
Management commentary
“Today’s communication infrastructure is critical to solving some of the biggest challenges facing our global society. And we are a key part of this process. We are the only remaining optical networking and synchronization specialist in Europe. Growing safety concerns, specifically around the major Chinese equipment suppliers, create new opportunities and unique selling points for us that further strengthen our market position,” said Brian Protiva, CEO, ADVA. “Technologically, our solutions are perfectly aligned with the network transformation that’s taking place, including a focus on cloud, mobility, 5G, network automation and security. With our investments, we’ve created a foundation for transforming our business model towards higher margins. This transformation includes growing revenue contributions from software and services, expansion into new industries and further verticalization of our business.”
“2020 was a challenging but very successful year for us. At the beginning of the pandemic, the uncertainties were high. However, we responded quickly to ensure that we could navigate through the crisis as best as possible. As a result, we’re reporting today one of the most successful financial years in the company’s history. In the final quarter, our pro forma operating income was even at 10.2% – a number that we have never achieved before,” commented Uli Dopfer, CFO, ADVA. “In addition, we were able to reduce our net debt substantially by EUR 36 million to around EUR 25 million – without the application of IFRS 16 this would correspond to net cash of around EUR 2 million. Therefore, we decided to terminate the KfW back-up line early in January. We are very confident about the coming year and started the new quarter with a well-filled order book and a favorable customer and product mix.”
Financial outlook 2021
For the fiscal year 2021, ADVA expects revenues to be in the range of EUR 580 million and EUR 610 million and a pro forma operating income of between 6.0% and 9.0% of revenues. For Q1 2021, the company expects revenues to be in the range of EUR 143 million and EUR 148 million and a proforma operating income of between 7.0% and 9.0% of revenues.
The company will publish its financial results for Q1 2021 on April 22, 2021.
Conference call details
ADVA will hold a conference call for analysts and investors today, February 25, 2021, to discuss the Q4 2020 and full year 2020 results. The company’s CEO, Brian Protiva, and CFO, Uli Dopfer, will host the call at 3:00 p.m. CET (9:00 a.m. EST). A question and answer session will follow management presentations.
A corresponding presentation is available on ADVA’s website: https://www.adva.com/en/about-us/investors/financial-results/conference-calls
The complete annual report 2020 (January – December) is available as a PDF here: https://www.adva.com/en/about-us/investors/financial-results/financial-statements
A replay of the call will be available here: https://www.adva.com/en/about-us/investors/financial-results/conference-calls
Forward-looking statements
The economic projections and forward-looking statements contained in this document relate to future facts. Such projections and forward-looking statements are subject to risks that cannot be foreseen and that are beyond the control of ADVA. ADVA is therefore not in a position to make any representation as to the accuracy of economic projections and forward-looking statements or their impact on the financial situation of ADVA or the market in the shares of ADVA.
Use of pro forma financial information
ADVA provides consolidated pro forma financial results in this press release solely as supplemental financial information to help investors and the financial community make meaningful comparisons of ADVA’s operating results from one financial period to another. ADVA believes that these pro forma consolidated financial results are helpful because they exclude non-cash charges related to the stock option programs and amortization and impairment of goodwill and acquisition-related intangible assets, which are not reflective of the company’s operating results for the period presented. Additionally, expenses related to restructuring measures are not included. This pro forma information is not prepared in accordance with IFRS and should not be considered a substitute for the historical information presented in accordance with IFRS.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005994/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
Macnica Appoints Sebastien Dignard as CEO of Atlantic Region to Accelerate Global Component-to-Solutions and Vertical Strategy5.1.2026 12:00:00 CET | Press release
Macnica leader to strengthen cross-regional collaboration across the Americas and Europe Macnica Inc. today announced the promotion of Sebastien Dignard to chief executive officer of the company’s Atlantic region. In this role, Dignard will lead Macnica’s business across North America, Europe and South America, accelerating the company’s component-to-solutions strategy and strengthening cross-regional collaboration to deliver long-term value for customers and partners across key verticals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105529342/en/ Sebastien Dignard, CEO, Macnica Atlantic Region Dignard previously served as president of Macnica Americas for two years where he led the organization through a period of growth and transformation across semiconductors, imaging, networking and advanced technologies. Under his leadership, the company shifted from a focus on individual components to value-driven solutions, ecosy
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
